Bárbara Ghizoni Maggi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bárbara Ghizoni Maggi has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Davi Orli Machado Grüdtner
Universidade Federal de Santa Catarina, Brasil
5 shared publications - Natan Lucca Lima
Faculty of Medicine, Federal University of Santa Catarina, Araranguá, Santa Catarina, Brazil
5 shared publications - Marcos Henrique da Silva Mezzari
Faculty of Medicine, Federal University of Santa Catarina, Araranguá, Brazil
4 shared publications - Gustavo Rassier Isolan
Centro Avançado de Neurologia e Neurocirurgia, Porto Alegre, RS, Brasil
2 shared publications - João Cândido Spezia de Souza
Faculty of Medicine, Federal University of Santa Catarina
2 shared publications - Luis Henrique Correa de Lara
Faculty of Medicine, Federal University of Santa Catarina
2 shared publications
Latest Publications
- 9 April 2026
- Published by Taylor & Francis in The Journal of Spinal Cord Medicine
- p. 1-12
Robotic exoskeleton-assisted walking performance in adults with motor-complete spinal cord injury: A systematic review and meta-analysis of single-arm studies
1. Patients with spinal cord injury (SCI) are often left with permanent loss of mobility, especially in the lower limbs, resulting in severe impairment of quality of life (1) and mobility (2–8). Th...
- 9 April 2026
- Published by Taylor & Francis in The Journal of Spinal Cord Medicine
- p. 1-12
Robotic exoskeleton-assisted walking performance in adults with motor-complete spinal cord injury: A systematic review and meta-analysis of single-arm studies
1. Patients with spinal cord injury (SCI) are often left with permanent loss of mobility, especially in the lower limbs, resulting in severe impairment of quality of life (1) and mobility (2–8). Th...
- 20 November 2025
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 38 (6) , 1-12
Regorafenib in adult patients with recurrent glioblastoma: a single-arm meta-analysis
Glioblastoma is an aggressive brain tumor with median survival under 2 years despite standard therapy. At recurrence, treatment options are limited, and regorafenib has emerged as a promising option. A systematic search was conducted through Pubmed, Cochrane Library, Embase, and Web of Science for studies on regorafenib in adult recurrent glioblastoma, and a single-arm meta-analysis with random-effects model was performed to pool the data. Across ten studies (724 patients), median overall survival (OS) was 7.2 months and median progression-free survival (PFS) was 2.6 months, with a 12-month OS of 22.5% and a 6-month PFS of 14.9%. Disease control rate (DCR) was 36.1%, including stable disease (SD) of 26.6% and a partial response of 8.5%; progressive disease occurred in 60.9%, and grade 3-4 adverse events in 31.4%. Meta-regression suggested MGMT methylation was associated with improved OS, PFS, DCR, and SD, while male sex was associated with better OS and SD. Overall, regorafenib demonstrated a predictable safety profile in recurrent glioblastoma, with outcomes potentially improved in male patients with MGMT-methylated tumors.
- 20 November 2025
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 38 (6) , 1-12
Regorafenib in adult patients with recurrent glioblastoma: a single-arm meta-analysis
Glioblastoma is an aggressive brain tumor with median survival under 2 years despite standard therapy. At recurrence, treatment options are limited, and regorafenib has emerged as a promising option. A systematic search was conducted through Pubmed, Cochrane Library, Embase, and Web of Science for studies on regorafenib in adult recurrent glioblastoma, and a single-arm meta-analysis with random-effects model was performed to pool the data. Across ten studies (724 patients), median overall survival (OS) was 7.2 months and median progression-free survival (PFS) was 2.6 months, with a 12-month OS of 22.5% and a 6-month PFS of 14.9%. Disease control rate (DCR) was 36.1%, including stable disease (SD) of 26.6% and a partial response of 8.5%; progressive disease occurred in 60.9%, and grade 3-4 adverse events in 31.4%. Meta-regression suggested MGMT methylation was associated with improved OS, PFS, DCR, and SD, while male sex was associated with better OS and SD. Overall, regorafenib demonstrated a predictable safety profile in recurrent glioblastoma, with outcomes potentially improved in male patients with MGMT-methylated tumors.
- 5 October 2025
- Published by Taylor & Francis in Pain Management
- Vol. 15 (12) , 1055-1063
Efficacy and safety of TNX-102 SL in patients with fibromyalgia: a systematic review and meta-analysis
TNX-102 SL is a new sublingual tablet formulation of cyclobenzaprine (CBP) for rapid transmucosal absorption. We aimed to evaluate the efficacy and safety of TNX-102 SL in improving pain and sleep quality in patients with fibromyalgia (FM). Searches were conducted in Embase, PubMed, Cochrane Library, and Web of Science databases. The primary endpoint was the reduction in daily diary pain score. Secondary outcomes included Fibromyalgia Impact Questionnaire (FIQ-R) Function and Symptoms, daily diary sleep score, and adverse effects. Four studies met eligibility criteria and a random-effect meta-analysis was performed to combine data. The analyses of 1,993 patients yielded statistically significant differences in the TNX-102 SL group versus the control group on daily diary pain intensity (SMD = -0.25; 95% CI [-0.34, -0.16]; p < 0.001), FIQ-R Function (SMD = -0.18; 95% CI [-0.35, -0.02]; p = 0.028), FIQ-R Symptoms (SMD = -0.23; 95% CI [-0.33, -0.13]; p < 0.001) and sleep daily diary (SMD = -0.21; 95% CI [-0.32, -0.11]; p < 0.001). Sedation, oral hypoaesthesia, and paresthesia were TNX102-SL's most common adverse effects. Pooled data show TNX-102 SL significantly reduces pain, improves sleep quality, and enhances quality of life in FM patients. www.crd.york.ac.uk/prospero identifier is CRD42024588069.
- 5 October 2025
- Published by Taylor & Francis in Pain Management
- Vol. 15 (12) , 1055-1063
Efficacy and safety of TNX-102 SL in patients with fibromyalgia: a systematic review and meta-analysis
TNX-102 SL is a new sublingual tablet formulation of cyclobenzaprine (CBP) for rapid transmucosal absorption. We aimed to evaluate the efficacy and safety of TNX-102 SL in improving pain and sleep quality in patients with fibromyalgia (FM). Searches were conducted in Embase, PubMed, Cochrane Library, and Web of Science databases. The primary endpoint was the reduction in daily diary pain score. Secondary outcomes included Fibromyalgia Impact Questionnaire (FIQ-R) Function and Symptoms, daily diary sleep score, and adverse effects. Four studies met eligibility criteria and a random-effect meta-analysis was performed to combine data. The analyses of 1,993 patients yielded statistically significant differences in the TNX-102 SL group versus the control group on daily diary pain intensity (SMD = -0.25; 95% CI [-0.34, -0.16]; p < 0.001), FIQ-R Function (SMD = -0.18; 95% CI [-0.35, -0.02]; p = 0.028), FIQ-R Symptoms (SMD = -0.23; 95% CI [-0.33, -0.13]; p < 0.001) and sleep daily diary (SMD = -0.21; 95% CI [-0.32, -0.11]; p < 0.001). Sedation, oral hypoaesthesia, and paresthesia were TNX102-SL's most common adverse effects. Pooled data show TNX-102 SL significantly reduces pain, improves sleep quality, and enhances quality of life in FM patients. www.crd.york.ac.uk/prospero identifier is CRD42024588069.
- 1 August 2025
- Published by Springer Nature in Neuroradiology
- p. 1-12
Early venous filling following reperfusion therapy in acute ischemic stroke: a systematic review and meta-analysis
Background Early venous filling (EVF), detected by digital subtraction angiography after endovascular therapy, may indicate hyperperfusion and vascular injury. Emerging evidence suggests that EVF is associated with adverse outcomes and complications, highlighting its potential role as a prognostic imaging marker in acute ischemic stroke (AIS). Methods A systematic search was conducted in the MEDLINE, Embase, Cochrane Library, and Web of Science databases to identify studies evaluating the outcomes of EVF following reperfusion therapy in cases of AIS. The outcomes included hemorrhagic transformation (HT), parenchymal hematoma (PH), hemorrhagic infarction (HI), symptomatic intracranial hemorrhage (sICH), cerebral infarction as hypodensity on imaging, malignant brain edema (MBE), and unfavorable outcome measured by modified Rankin scale (mRS ≥ 3) after 90 days. A meta-analysis using a random-effects model was conducted to pool the data. Results In the data analyses of 12 studies and 2,446 patients, the presence of EVF post-reperfusion was associated with increased risks of HT (odds ratio [OR] = 4.31; 95% confidence interval [CI] [3.00, 6.21]; p < 0.001), PH (OR = 5.73; 95% CI [2.82, 11.65]; p < 0.001), sICH (OR = 6.43; 95% CI [3.49, 8.47]; p < 0.001), cerebral infarction (OR = 15.95; 95% CI [6.37, 39.92]; p < 0.001), MBE (OR = 3.69; 95% CI [2.26, 6.04]; p < 0.001), and unfavorable functional outcomes (OR = 2.58; 95% CI [1.27, 5.23]; p = 0.009). Conclusions EVF may serve as a predictor of increased risk of hemorrhagic events, cerebral infarction on imaging, MBE, and unfavorable functional outcomes after brain reperfusion therapy. Graphical Abstract
- 1 August 2025
- Published by Springer Nature in Neuroradiology
- p. 1-12
Early venous filling following reperfusion therapy in acute ischemic stroke: a systematic review and meta-analysis
Background Early venous filling (EVF), detected by digital subtraction angiography after endovascular therapy, may indicate hyperperfusion and vascular injury. Emerging evidence suggests that EVF is associated with adverse outcomes and complications, highlighting its potential role as a prognostic imaging marker in acute ischemic stroke (AIS). Methods A systematic search was conducted in the MEDLINE, Embase, Cochrane Library, and Web of Science databases to identify studies evaluating the outcomes of EVF following reperfusion therapy in cases of AIS. The outcomes included hemorrhagic transformation (HT), parenchymal hematoma (PH), hemorrhagic infarction (HI), symptomatic intracranial hemorrhage (sICH), cerebral infarction as hypodensity on imaging, malignant brain edema (MBE), and unfavorable outcome measured by modified Rankin scale (mRS ≥ 3) after 90 days. A meta-analysis using a random-effects model was conducted to pool the data. Results In the data analyses of 12 studies and 2,446 patients, the presence of EVF post-reperfusion was associated with increased risks of HT (odds ratio [OR] = 4.31; 95% confidence interval [CI] [3.00, 6.21]; p < 0.001), PH (OR = 5.73; 95% CI [2.82, 11.65]; p < 0.001), sICH (OR = 6.43; 95% CI [3.49, 8.47]; p < 0.001), cerebral infarction (OR = 15.95; 95% CI [6.37, 39.92]; p < 0.001), MBE (OR = 3.69; 95% CI [2.26, 6.04]; p < 0.001), and unfavorable functional outcomes (OR = 2.58; 95% CI [1.27, 5.23]; p = 0.009). Conclusions EVF may serve as a predictor of increased risk of hemorrhagic events, cerebral infarction on imaging, MBE, and unfavorable functional outcomes after brain reperfusion therapy. Graphical Abstract
- 29 April 2025
- Published by Springer Nature in Neurosurgical Review
- Vol. 48 (1) , 1-12
Intrathecal nicardipine for cerebral vasospasm after non-traumatic subarachnoid hemorrhage: a meta-analysis
Cerebral vasospasm is a common and serious complication following non-traumatic subarachnoid hemorrhage (SAH), often leading to worsened outcomes, especially when associated with delayed cerebral ischemia (DCI). Intrathecal nicardipine has shown potential as a treatment for vasospasm, although further research is needed to establish its effectiveness and determine its role in managing this complication. A systematic search was conducted through MEDLINE, Embase, Cochrane Library, and Web of Science databases to identify studies comparing outcome measures for intrathecal nicardipine after SAH with a control group. The primary endpoints were vasospasm severity, DCI rate, and favorable outcome at 1–6 months, assessed by functional outcome scales. Secondary outcomes included mortality, infection rates, and the need for shunt placement. A total of six studies met the eligibility criteria, and a meta-analysis using a random-effects model was conducted to pool the data. In the data analyses of 2,569 patients, in comparison with standard therapy, nicardipine use has shown statistical significance in reducing the incidence of mild vasospasm (odds ratio [OR] = 0.40; 95% confidence interval [CI] [0.20, 0.80]; p = 0.010; 𝐼² = 0%), reducing mortality rate (OR = 0.58; 95% CI [0.42, 0.81]; p = 0.001; 𝐼² = 0%), and increasing infection rate, including ventriculitis and meningitis (OR = 2.54; 95% CI [1.05, 6.19]; p = 0.040; 𝐼² = 51%). The results of this present study indicate that intrathecal nicardipine may be an effective therapeutic option for reducing the severity of vasospasm and improving mortality rates in patients with non-traumatic SAH. However, it may increase the risk of infections. Further research with randomized controlled trials is needed to confirm these findings and evaluate this treatment’s long-term benefits and risks.
- 29 April 2025
- Published by Springer Nature in Neurosurgical Review
- Vol. 48 (1) , 1-12
Intrathecal nicardipine for cerebral vasospasm after non-traumatic subarachnoid hemorrhage: a meta-analysis
Cerebral vasospasm is a common and serious complication following non-traumatic subarachnoid hemorrhage (SAH), often leading to worsened outcomes, especially when associated with delayed cerebral ischemia (DCI). Intrathecal nicardipine has shown potential as a treatment for vasospasm, although further research is needed to establish its effectiveness and determine its role in managing this complication. A systematic search was conducted through MEDLINE, Embase, Cochrane Library, and Web of Science databases to identify studies comparing outcome measures for intrathecal nicardipine after SAH with a control group. The primary endpoints were vasospasm severity, DCI rate, and favorable outcome at 1–6 months, assessed by functional outcome scales. Secondary outcomes included mortality, infection rates, and the need for shunt placement. A total of six studies met the eligibility criteria, and a meta-analysis using a random-effects model was conducted to pool the data. In the data analyses of 2,569 patients, in comparison with standard therapy, nicardipine use has shown statistical significance in reducing the incidence of mild vasospasm (odds ratio [OR] = 0.40; 95% confidence interval [CI] [0.20, 0.80]; p = 0.010; 𝐼² = 0%), reducing mortality rate (OR = 0.58; 95% CI [0.42, 0.81]; p = 0.001; 𝐼² = 0%), and increasing infection rate, including ventriculitis and meningitis (OR = 2.54; 95% CI [1.05, 6.19]; p = 0.040; 𝐼² = 51%). The results of this present study indicate that intrathecal nicardipine may be an effective therapeutic option for reducing the severity of vasospasm and improving mortality rates in patients with non-traumatic SAH. However, it may increase the risk of infections. Further research with randomized controlled trials is needed to confirm these findings and evaluate this treatment’s long-term benefits and risks.